The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

In addition to tirzepatide’s application in obesity and type 2 diabetes (T2D), it is also in pre-registration for obstructive ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

The American Heart Association and the Arizona Cardinals gathered representatives from 12 local schools for cardiopulmonary ...

Footage of a man being shoved into a wall by a police officer before being dragged through a front yard has been shared on social media, with SA Police confirming a formal complaint has been made ...

Covering Netflix News Independently Since 2013. What’s on Netflix is not owned by or affiliated with Netflix or any of its partners in any capacity. The authors of this site also have no affiliation ...